OBJECTIVE: To determine whether donepezil is effective in enhancing cognitive functioning and instrumental activities of daily living (IADLs) in older adults with bipolar disorder. METHODS: Twelve elderly patients with bipolar I or II disorder, with evidence of mild cognitive decrements, were administered donepezil 5-10 mg daily for 3 months. Participants had cognitive and functional evaluation pre-, on-, and 3-months post donepezil administration. RESULTS: Three subjects dropped out of the study. In the remaining nine subjects, no significant effects were observed in cognitive and functional measures. Seven of the nine participants asked to resume the medication after completion of the study because of the perceived beneficial effects. CONCLUSIONS: In this small pilot study of older adults with bipolar disorder, acute treatment with donepezil was not associated with improvements in cognitive and IADL functioning. Given limitations of the study design, placebo effects could not be ruled out in the subjects who asked to resume donepezil.
OBJECTIVE: To determine whether donepezil is effective in enhancing cognitive functioning and instrumental activities of daily living (IADLs) in older adults with bipolar disorder. METHODS: Twelve elderly patients with bipolar I or II disorder, with evidence of mild cognitive decrements, were administered donepezil 5-10 mg daily for 3 months. Participants had cognitive and functional evaluation pre-, on-, and 3-months post donepezil administration. RESULTS: Three subjects dropped out of the study. In the remaining nine subjects, no significant effects were observed in cognitive and functional measures. Seven of the nine participants asked to resume the medication after completion of the study because of the perceived beneficial effects. CONCLUSIONS: In this small pilot study of older adults with bipolar disorder, acute treatment with donepezil was not associated with improvements in cognitive and IADL functioning. Given limitations of the study design, placebo effects could not be ruled out in the subjects who asked to resume donepezil.
Authors: Ariel G Gildengers; Benoit H Mulsant; Amy E Begley; Mary McShea; Jacqueline A Stack; Mark D Miller; Andrea Fagiolini; David J Kupfer; Robert C Young; Charles F Reynolds Journal: Am J Geriatr Psychiatry Date: 2005-04 Impact factor: 4.105
Authors: Ronald C Petersen; Ronald G Thomas; Michael Grundman; David Bennett; Rachelle Doody; Steven Ferris; Douglas Galasko; Shelia Jin; Jeffrey Kaye; Allan Levey; Eric Pfeiffer; Mary Sano; Christopher H van Dyck; Leon J Thal Journal: N Engl J Med Date: 2005-04-13 Impact factor: 91.245
Authors: Ulderico Freo; Emiliano Ricciardi; Pietro Pietrini; Mark B Schapiro; Stanley I Rapoport; Maura L Furey Journal: Am J Psychiatry Date: 2005-11 Impact factor: 18.112
Authors: J A Yesavage; M S Mumenthaler; J L Taylor; L Friedman; R O'Hara; J Sheikh; J Tinklenberg; P J Whitehouse Journal: Neurology Date: 2002-07-09 Impact factor: 9.910
Authors: Martin S Mumenthaler; Jerome A Yesavage; Joy L Taylor; Ruth O'Hara; Leah Friedman; Hana Lee; Helena C Kraemer Journal: Neuropsychopharmacology Date: 2003-05-14 Impact factor: 7.853
Authors: Ariel G Gildengers; Meryl A Butters; Karen Seligman; Mary McShea; Mark D Miller; Benoit H Mulsant; David J Kupfer; Charles F Reynolds Journal: Am J Psychiatry Date: 2004-04 Impact factor: 18.112
Authors: Marsal Sanches; Isabelle E Bauer; Juan F Galvez; Giovana B Zunta-Soares; Jair C Soares Journal: Am J Ther Date: 2015 Nov-Dec Impact factor: 2.688
Authors: Ariel G Gildengers; Benoit H Mulsant; Amy Begley; Sati Mazumdar; Adriana V Hyams; Charles F Reynolds Iii; David J Kupfer; Meryl A Butters Journal: Bipolar Disord Date: 2009-08-28 Impact factor: 6.744
Authors: Brisa Solé; Esther Jiménez; Carla Torrent; Maria Reinares; Caterina Del Mar Bonnin; Imma Torres; Cristina Varo; Iria Grande; Elia Valls; Estela Salagre; Jose Sanchez-Moreno; Anabel Martinez-Aran; André F Carvalho; Eduard Vieta Journal: Int J Neuropsychopharmacol Date: 2017-08-01 Impact factor: 5.176